CD8A and neoplasm: Prior literature suggests that TCRαβVβ1+, but not TCRαβVβ2+ T cells are important for the development of anti-MDV serotype 2 (non-oncogenic MDV) vaccinal immunity [85], and analysis of T cell clonality in MD tumors has identified vigorous TCR Vβ1 clonal responses within intra-tumor CD8+ subsets [86].